| Literature DB >> 31813345 |
Agostino Virdis1, Stefano Masi1, Edoardo Casiglia2, Valerie Tikhonoff3, Arrigo F G Cicero4, Andrea Ungar5, Giulia Rivasi5, Massimo Salvetti6, Carlo M Barbagallo7, Michele Bombelli8, Raffaella Dell'Oro8, Berardino Bruno9, Luciano Lippa10, Lanfranco D'Elia11, Paolo Verdecchia12, Francesca Mallamaci13, Massimo Cirillo14, Marcello Rattazzi15, Pietro Cirillo16, Loreto Gesualdo16, Alberto Mazza17, Cristina Giannattasio17, Alessandro Maloberti18, Massimo Volpe19,20, Giuliano Tocci19,20, Georgios Georgiopoulos21, Guido Iaccarino22, Pietro Nazzaro23, Gianfranco Parati24, Paolo Palatini2, Ferruccio Galletti11, Claudio Ferri9, Giovambattista Desideri9, Francesca Viazzi25, Roberto Pontremoli25, Maria Lorenza Muiesan6, Guido Grassi8, Claudio Borghi4.
Abstract
Serum uric acid (SUA) levels discriminating across the different strata of cardiovascular risk is still unknown. By utilizing a large population-based database, we assessed the threshold of SUA that increases the risk of total mortality and cardiovascular mortality (CVM). The URRAH study (Uric Acid Right for Heart Health) is a multicentre retrospective, observational study, which collected data from several large population-based longitudinal studies in Italy and subjects recruited in the hypertension clinics of the Italian Society of Hypertension. Total mortality was defined as mortality for any cause, CVM as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. A total of 22 714 subjects were included in the analysis. Multivariate Cox regression analyses identified an independent association between SUA and total mortality (hazard ratio, 1.53 [95% CI, 1.21-1.93]) or CVM (hazard ratio, 2.08 [95% CI, 1.146-2.97]; P<0.001). Cutoff values of SUA able to discriminate total mortality (4.7 mg/dL [95% CI, 4.3-5.1 mg/dL]) and CVM status (5.6 mg/dL [95% CI, 4.99-6.21 mg/dL]) were identified. The information on SUA levels provided a significant net reclassification improvement of 0.26 and of 0.27 over the Heart Score risk chart for total mortality and CVM, respectively (P<0.001). Sex-specific cutoff values for total mortality and CVM were also identified and validated. In conclusion, SUA levels increasing the risk of total mortality and CVM are significantly lower than those used for the definition of hyperuricemia in clinical practice. Our data provide evidence of a cardiovascular SUA threshold that might contribute in clinical practice to improve identification of patients at higher risk of CVM.Entities:
Keywords: epidemiology; heart failure; humans; risk; uric acid
Year: 2019 PMID: 31813345 DOI: 10.1161/HYPERTENSIONAHA.119.13643
Source DB: PubMed Journal: Hypertension ISSN: 0194-911X Impact factor: 10.190